

2013 7th call - Health theme - Contacts

25/04/2012

Areas / Sub-Area	Topic	Topic title	Funding scheme	Unit	Project Officer(s)	E-mail	
0. Key strategic cross-cutting issues	0-1	Boosting the translation of FP projects' results into innovative applications for health	SBIR-like		All		
1.1. HIGH-THROUGHPUT RESEARCH		CLOSED					
1.2. DETECTION, DIAGNOSIS & MONITORING	1.2-1	Development of imaging technologies for therapeutic interventions in rare diseases	CP-SME	F5	Philippe JEHENSON	Philippe.Jehenson@ec.europa.eu	
1.3. SUITABILITY, SAFETY, EFFICACY OF THERAPIES	1.3-1	Modelling toxic responses in case studies for predictive human safety assessment	CP-IP	F4	Jürgen Busing	Juergen.Buesing@ec.europa.eu	
	1.3-2	Innovative approaches to address adverse immune reactions to biomedical devices, implants and transplant tissues	CP-FP	F4	Bernd Rainer	Bernd.Rainer@ec.europa.eu	
	1.3-3	Safety and efficacy of therapeutics vaccines	CP-FP	F4	Andreas Holtel	Andreas.Holtel@ec.europa.eu	
	1.3-4	Development of alternative <i>in vitro</i> , analytical, immunochemical, and other test methods for quality control of vaccines	CP-FP	F4	Andreas Holtel	Andreas.Holtel@ec.europa.eu	
1.4. INNOVATIVE THERAPIES	1.4-1	Controlling differentiation and proliferation in human stem cells intended for therapeutic use	CP-FP	F4	Kessler,Sautter,Gancberg	Charles.Kessler@ec.europa.eu ; Juergen.Sautter@ec.europa.eu ; David.Gancberg@ec.europa.eu	
2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES	2.1.1. Large scale data gathering	2.1.1-1	Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes	CP-SME	F5	Dirk HADRICH	Dirk.Hadrich@ec.europa.eu
		2.1.1-2	High impact research initiative on metagenomics for personalised medicine approaches	CP-IP	F5	Dirk HADRICH	Dirk.Hadrich@ec.europa.eu
	2.1.2. Systems Biology		CLOSED				
2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN DEVELOPMENT AND AGEING	2.2.1. Brain and related disorders	2.2.1-1	Prospective longitudinal data collection and Comparative Effectiveness Research for traumatic brain injury (TBI)	CP-IP	F2	P. Tosetti & Ph. Cupers	patrizia.tosetti@ec.europa.eu ; philippe.cupers@ec.europa.eu
		2.2.1-2	Development of more effective imaging tools for diagnosis, monitoring and management of mental disorders	CP-FP	F2	P. Tosetti & M. Goldammer	patrizia.tosetti@ec.europa.eu ; mark.goldammer@ec.europa.eu
		2.2.1-3	Paediatric conduct disorders characterised by aggressive traits and / or social impairment: from preclinical research to treatment	CP-FP	F2	Ph. Cupers & S. Weiland	philippe.cupers@ec.europa.eu ; sigrid.weiland@ec.europa.eu
		2.2.1-4	Patho-physiology and therapy of epilepsy and epileptiform disorders	CP-FP	F2	P. Tosetti & S. Weiland	patrizia.tosetti@ec.europa.eu ; sigrid.weiland@ec.europa.eu
		2.2.1-5	Understanding and controlling pain	CP-FP	F2	Ph. Cupers & M. Goldammer	philippe.cupers@ec.europa.eu ; mark.goldammer@ec.europa.eu
	2.2.2. Human development and ageing		CLOSED				
2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES	2.3.0 Cross cutting	2.3.0-1	Innovation in vaccines	CP-SME	F3	Christian Desaintes, Ole Olesen	christian.DESAINTES@ec.europa.eu ; ole.OLESEN@ec.europa.eu
	2.3.1. Anti-microbial drug resistance	2.3.1-1	Drugs and vaccines for infections that have developed or are at the risk of developing significant anti-microbial resistance	SBIR-like	F3	Arjon Van Hengel	Adrianus.VAN-HENGEL@ec.europa.eu
		2.3.1-2	Stratified approaches to antibacterial and/or antifungal treatment	CP-FP	F3	Arjon Van Hengel	Adrianus.VAN-HENGEL@ec.europa.eu
	2.3.2. HIV/AIDS, TB, Malaria		CLOSED				
	2.3.3. Emerging epidemics	2.3.3-1	Clinical management of patients in severe epidemics	CP-IP	F3	Christian Desaintes	christian.DESAINTES@ec.europa.eu
	2.3.4 Neglected diseases	2.3.4-1	Neglected infectious diseases in Central- and Eastern Europe	CP-FP	F3	Ole Olesen	ole.OLESEN@ec.europa.eu
2.3.4-2		Drug development for neglected parasitic diseases	CP-SME	F3	Ole Olesen	ole.OLESEN@ec.europa.eu	
2.4. TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES	2.4.1. Cancer	2.4.1-1	Investigator-driven treatment trials to combat or prevent metastases in patients with solid cancer	CP-FP	F2	J van de Loo, N Trzaska	jan-willem-van-de-loo@ec.europa.eu ; Dominika.TRZASKA@ec.europa.eu
		2.4.1-2	Strengthening the cancer patient's immune system	CP-FP	F2	J van de Loo, N Trzaska	jan-willem-van-de-loo@ec.europa.eu ; Dominika.TRZASKA@ec.europa.eu
		2.4.1-3	Investigator-driven supportive and palliative care clinical trials and observational studies	CP-FP	F2	J van de Loo, N Trzaska	jan-willem-van-de-loo@ec.europa.eu ; Dominika.TRZASKA@ec.europa.eu
	2.4.2. Cardiovascular diseases	2.4.2-1	Discovery research to reveal novel targets for cardiovascular disease treatment	CP-SME	F2	V Dambrauskaite	Virginija.DAMBRAUSKAITE@ec.europa.eu
		2.4.2-2	Comparative effectiveness research of existing tools for prevention, diagnosis and treatment of cardiovascular diseases	CP-FP	F2	V Dambrauskaite	Virginija.DAMBRAUSKAITE@ec.europa.eu
		2.4.2-3	Optimising lifestyle interactions in the prevention and treatment of cardiovascular disease across the lifespan	CP-FP	F2	V Dambrauskaite	Virginija.DAMBRAUSKAITE@ec.europa.eu

2013 7th call - Health theme - Contacts

25/04/2012

Areas / Sub-Area	Topic	Topic title	Funding scheme	Unit	Project Officer(s)	E-mail	
	2.4.3. Diabetes and obesity	CLOSED					
	2.4.4. Rare diseases	CLOSED					
	2.4.5. Other chronic diseases	CLOSED					
P I L L A R 3	3.1. TRANSLATING THE RESULTS OF CLINICAL RESEARCH OUTCOME INTO CLINICAL PRACTICE	3.1-1	Comparative Effectiveness Research (CER) in health systems and health services interventions	CP-FP	F3	Barbara Kerstiens	Barbara.KERSTIENS@ec.europa.eu
	3.2. QUALITY, EFFICIENCY AND SOLIDARITY OF HEALTHCARE SYSTEMS INCLUDING TRANSITIONAL HEALTH SYSTEMS		CLOSED				
	3.3. HEALTH PROMOTION AND PREVENTION	3.3-1	Social innovation for health promotion	CP-FP	F3	Caroline Attard	Caroline.ATTARD@ec.europa.eu
	3.4. INTERNATIONAL PUBLIC HEALTH & HEALTH SYSTEMS						
4.1. COORDINATION AND SUPPORT ACTIONS ACROSS THE THEME	4.1-1	Supporting industrial participation in EU-funded research in the health sector	CA	F1	Ludovica Serafini	Ludovica.serafini@ec.europa.eu	
	4.1-2	Interactions between EU legislation and health research and/or innovation	SA	F1	Joana Namorado	joana.namorado@ec.europa.eu	
	4.1-3	Support for Presidency events	SA	F1	Peter Loffler	peter.loffler@ec.europa.eu	
	4.1-4	Preparing the future for health research and innovation	SA	F1	Olivier Le Dour	olivier.le-dour@ec.europa.eu	
	4.1-5	Global initiative on gene-environment interactions in diabetes/obesity in specific populations.	CA	F2	K. Berkouk, N. Vercauysse	karim.berkouk@ec.europa.eu , nathalie.vercauysse@ec.europa.eu	
	4.1-6	Mapping chronic non-communicable diseases research activities.	CA	F2	K. Berkouk	karim.berkouk@ec.europa.eu	
4.2. RESPONDING TO EU POLICY NEEDS	4.2-1	Investigator-driven clinical trials for off-patent medicines using innovative, age-appropriate formulations and/or delivery systems addressing one of the options given in the topic description	CP-FP	F5	Alexandru COSTESCU	Alexandru-Sorin.Costescu@ec.europa.eu	
	4.2-2	Adverse drug reaction research.	CP-FP	F5	Iiro EEROLA	Iiro.Eerola@ec.europa.eu	
	4.2-3	New methodologies for clinical trials for small population groups	CP-FP	F5	Irene NORSTEDT	Irene.Norstedt@ec.europa.eu	